Benzodiazole-indole derivatives for detecting aging-related β-galactosidase, their preparation methods and applications
By synthesizing benzo[a]diazole-indole derivatives, the problem of diffusion of hydrolysis products of existing probes was solved, enabling in-situ detection of β-galactosidase and achieving precise detection at the cellular and in vivo levels.
Patent Information
- Application Number
- CN202611327557.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-31
- Publication Date
- 2026-11-17
AI Technical Summary
Existing β-galactosidase fluorescent probes have the problem that hydrolysis products are easily diffused, making in-situ detection impossible and making it difficult to accurately detect aging-related β-galactosidases.
We designed and synthesized benzo[a]diazole-indole derivatives, which specifically recognize β-galactosidase and, combined with protein anchoring technology, inhibit the diffusion of hydrolysis products, thus enabling in-situ detection.
It enables in situ detection of β-galactosidase, and can accurately detect aging-related β-galactosidase at the cellular and in vivo levels, with high selectivity and anti-interference ability.
Smart Images

Figure CN123106791A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a class of benzo[a]diazole-indole derivatives for the self-anchored detection of aging-related β-galactosidases, their preparation methods and applications, belonging to the field of medicinal chemistry technology. Background Technology
[0002] Cellular senescence is an important physiological process activated by external damage or pathological stimuli. However, this process inhibits the tissue's repair potential and promotes the development of age-related diseases, leading to the decline of bodily functions. The causes of aging in organisms can be traced back to the cumulative effect of cellular senescence. In this process, senescent cells secrete various senescence-related factors, which affect surrounding healthy cells and tissues, causing functional impairment and driving the pathological progression of age-related diseases. Therefore, precise detection of senescent cells and quantitative analysis of aging phenotypes are not only key tools for revealing the heterogeneity of aging in organisms but also provide important evidence for the discovery of biomarkers for age-related diseases. Fluorescent probes, due to their high spatiotemporal resolution and ease of operation, have been widely used for the detection and visualization of aging-related β-galactosidases in biological systems. However, existing β-galactosidase fluorescent probes suffer from problems such as the easy diffusion of hydrolysis products and the inability to detect them in situ, which urgently need to be addressed. Summary of the Invention
[0003] In view of this, the purpose of this invention is to provide a benzo[a]diazole-indole derivative for in situ detection of aging-related β-galactosidase, its preparation method, and its application. In this design, when R = H, the recognition site can be specifically recognized by β-galactosidase, and this type of compound is a specific substrate for β-galactosidase; when R = a C1-C10 alkyl acyl group, this type of compound can be hydrolyzed into a natural substrate by esterases in vivo.
[0004] The benzo[i]diazole-indole derivatives represented by general structural formula (I) (I) R is selected from H or C1-C10 alkanoyl groups (the alkanoyl group is a group formed by an alkyl group attached to the molecular body through a carbonyl group (C=O)), X is OH or F, and n = 1~10; R is preferably selected from H or C1-C6 alkanoyl groups, X is OH or F, and n = 1~6; R is more preferably selected from H or C1-C4 alkanoyl groups, X is OH or F, and n = 1~4; R is most preferably selected from H or acetyl groups, X is OH or F, and n = 1 or 2.
[0005] The above-mentioned method for synthesizing benzo[a]diazole-indole derivatives is selected from the following steps: (1) Compound A reacts with compound B via an organic base catalysis to yield compound C; , n = 1~10; (2) Compound C and compound D undergo an amidation reaction in the presence of a condensing agent to yield compound (I); , R is selected from H or C1-C10 alkanoyl groups, and X is OH or F.
[0006] In the above method for synthesizing benzo[a]diazole-indole derivatives, in step (1), the organic solvent used is selected from acetonitrile, methanol, ethanol, isopropanol, toluene, and benzene; the organic base used is selected from hexahydropyridine, pyridine, triethylamine, and N,N-diisopropylethylamine.
[0007] In the above method for synthesizing benzo[a]diazole-indole derivatives, in step (2), the organic solvent used is selected from acetonitrile, dichloromethane, 1,4-dioxane, tetrahydrofuran, and N,N-dimethylformamide; the organic base used is selected from hexahydropyridine, pyridine, triethylamine, and N,N-diisopropylethylamine; and the condensing reagent used is selected from 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and benzo[a]triazole-1-yl-oxytripyrrolidinephosphide hexafluorophosphate.
[0008] Compound I-OH reacts with a fluorinating agent to give compound IF, wherein the fluorinating agent is selected from diethylaminosulfur trifluoride, N-fluorobisbenzenesulfonamide, thiomorpholine trifluoride, or bis-(2-methoxyethyl)aminesulfur trifluoride; ; The organic solvents used above are selected from acetonitrile, dichloromethane, 1,4-dioxane, tetrahydrofuran, and N,N-dimethylformamide.
[0009] Compound IR was transesterified to give compound IH; .
[0010] The organic solvents used in the above reactions are selected from acetonitrile, dichloromethane, 1,4-dioxane, tetrahydrofuran, and N,N-dimethylformamide, and the inorganic bases are selected from potassium carbonate, sodium carbonate, and cesium carbonate.
[0011] The aforementioned benzo[a]diazole-indole derivative can be visualized to detect senescent cells enriched with β-galactosidase, enabling precise detection of senescent cells. The active molecules generated by the reaction with β-galactosidase can be anchored in senescent cells, and the molecular rigidity is enhanced in the protein microenvironment, thereby producing obvious changes in optical signals, thus achieving in situ detection of β-galactosidase.
[0012] Therefore, the above-mentioned benzo[a]diazole-indole derivatives have one or more of the following applications: (1) A composition or preparation for the detection of β-galactosidase; (2) Compositions or preparations for the preparation of samples for detecting β-galactosidase activity at the molecular, cellular and in vivo animal levels; (3) Compositions or preparations for selectively recognizing and anchoring cells with high expression of β-galactosidase.
[0013] Pharmaceutical compositions, cosmetic compositions, food compositions, or health product compositions containing the above-mentioned benzo[a]diazole-indole derivatives, wherein the compositions contain a compound of general structural formula (I) and a pharmaceutically acceptable carrier or excipient; the compositions are tablets, capsules, granules, suspensions, pills, solutions, syrups, or injections.
[0014] The present invention has the following significant advantages: (1) This series of benzo[a]diazole-indole derivatives, combined with β-galactosidase targeting technology and protein anchoring technology, can inhibit the diffusion of hydrolysis products, thereby realizing the in-situ detection of β-galactosidase. (2) This series of benzo[a]diazole-indole derivatives can realize the detection of senescent cells at the cellular level and in vivo level. Attached Figure Description
[0015] Figure 1 For I-3 / I-4 and Aspergillus oryzae β-galactosidase ( A. oryzae Changes in UV absorption and fluorescence emission spectra before and after the reaction of β-gal and reduced bovine serum albumin (rBSA); Figure 2 For I-3 / I-4 in rBSA solution A. oryzae Selectivity and interference experiments of β-gal, as well as enzyme kinetics and pH response experiments; Figure 3 For I-3 / I-4 cytotoxicity assays; Figure 4 Confocal imaging experiments for cells I-3 / I-4;
[0016] Figure 5 This demonstrates the ability of I-4 to detect senescent cells in mice. Detailed Implementation
[0017] The inventors of this application, through extensive and in-depth research, designed and synthesized a series of benzo[a]diazole-indole derivatives for the self-anchored detection of aging-related β-galactosidases, where R includes, but is not limited to, hydrogen, acetyl, and propionyl groups. Upon activation by β-galactosidase, these derivatives rapidly release active molecules and anchor within senescent cells, enabling in situ detection of aging-related β-galactosidases at both the cellular and in vivo levels. Based on this, the present invention was completed.
[0018] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions or as recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and parts by weight.
[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as are familiar to those skilled in the art. Furthermore, any methods and materials similar to or equivalent to those described herein may be applied to the methods of this invention. The preferred embodiments and materials described herein are for illustrative purposes only.
[0020] Example 1 Preparation of compound C-1
[0021] (Compound C-1) Compound 7-(1-pyrrolidinyl)benzo[c][1,2,5]diazole-4-carboxaldehyde (1.50 g, 6.91 mmol) and 1-(2-carboxyethyl)-2,3,3-trimethyl-3H-indol-1-yl bromide (2.15 g, 6.91 mmol) were dissolved in anhydrous ethanol (70 mL), 5 drops of piperidine were added, the mixture was refluxed and stirred overnight, cooled to room temperature and filtered under an ice bath, the filter cake was washed with ice-cold ethanol, recrystallized from ethanol, and dried under vacuum to give a blue-violet solid compound C-1 (1.59 g, 45.0%). 1 H NMR (400MHz, CD3OD): δ 8.43 (d, J = 15.2 Hz, 1H), 8.07 (d, J = 8.7 Hz, 1H), 7.75 (d, J = 15.2 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.62 (dd, J = 7.5, 1.3 Hz, 1H), 7.52 (td, J= 7.8, 1.3 Hz, 1H), 7.44 (td, J = 7.5, 0.9 Hz, 1H), 6.46 (d, J =8.6 Hz, 1H), 4.63 (t, J = 7.4 Hz, 2H), 4.34 (s, 2H), 3.79 (s, 2H), 2.78 (t, J = 7.4 Hz, 2H), 2.20 (s, 4H), 1.81 (s, 6H). 13 C NMR (100 MHz, DMSO- d 6 ): δ178.64, 149.43, 148.20, 144.96, 143.48, 142.49, 141.14, 128.79, 127.22,122.88, 113.47, 107.66, 106.52, 106.31, 50.63, 48.62, 43.55, 26.55, 22.09,21.72. HRMS (ESI + ): m / z calcd for [M-Br] + , 431.2077; found, 431.2072.
[0022] Preparation of compound I-1
[0023] (Compound I-1) Compound C-1 (510 mg, 1.00 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (HATU) (380.00 mg, 1.20 mmol) were dissolved in N,N-dimethylformamide (15 mL), and then N,N-diisopropylethylamine (DIPEA) (252 mg, 2.00 mmol) was added and stirred for 20 minutes. The solution was then dissolved in 0 mL of N,N-dimethylformamide (15 mL). oCompound (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-(1-hydroxy-2-oxo-2-(piperazin-1-yl)ethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triol triacetate (566 mg, 1.00 mmol) was added at C and reacted for 1 hour. After the reaction was completed by TLC monitoring, the reaction mixture was cooled to room temperature, diluted with dichloromethane (50 mL), and washed several times with saturated sodium chloride solution. The solvent was evaporated from the dichloromethane phase, and the crude product was purified by silica gel column chromatography (eluent: DCM / MeOH: 10 / 1, V / V) to give a blue-violet solid compound I-1 (587 mg, 60%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.53 (d, J =15.2 Hz, 1H), 8.33 (d, J = 8.7 Hz, 1H), 7.77 (d, J = 7.4 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.54 – 7.43 (m, 3H), 7.30 (dd, J = 13.5, 8.3 Hz, 2H), 6.96(dd, J = 12.3, 8.5 Hz, 2H), 6.59 (d, J = 8.8 Hz, 1H), 5.46 (dd, J = 15.7, 7.8Hz, 1H), 5.33 (s, 1H), 5.31 – 5.24 (m, 1H), 5.20 (t, J = 8.8 Hz, 1H), 5.16(s, 1H), 4.55 (t, J = 6.8 Hz, 2H), 4.46 – 4.36 (m, 1H), 4.27 (s, 2H), 4.07(dd, J = 16.5, 6.2 Hz, 2H), 3.79 (s, 2H), 3.50 – 3.37 (m, 5H), 3.24 (d, J =4.4 Hz, 3H), 3.00 (s, 2H), 2.22 – 2.08 (m, 7H), 2.00 (dd, J= 16.4, 10.5 Hz, 6H), 1.95 (s, 3H), 1.78 (s, 6H). 13 C NMR (100 MHz, DMSO- d 6 ): δ 179.29, 178.88,169.99, 169.83, 169.59, 169.25, 168.03, 167.82, 164.61, 162.30, 156.27,148.34, 145.12, 143.70, 142.39, 141.15, 131.32, 128.76, 127.20, 122.72,116.29, 107.66, 106.47, 97.63, 70.39, 70.16, 68.36, 67.24, 61.29, 56.59,50.76, 50.60, 44.51, 38.22, 35.76, 30.73, 30.01, 26.49, 26.40, 25.49, 24.18,20.42, 20.38, 20.32. HRMS (ESI + ): m / z calcd for [M-Br] + , 979.4084; found,979.4106.
[0024] Preparation of compound I-2
[0025] (Compound I-2) Compound I-1 (106 mg, 0.10 mmol) was dissolved in dichloromethane (15 mL) and heated at -78°C. o At temperature C, diethylaminosulfur trifluoride (DAST) (80.5 mg, 0.10 mmol) was added, and the mixture was stirred for approximately 6 hours before naturally warming to room temperature. After the reaction was completed by TLC monitoring, saturated sodium chloride solution was added for extraction. The solvent was removed by evaporation of the dichloromethane phase, and the crude product was purified by silica gel column chromatography (eluent: DCM / MeOH: 100 / 1, V / V) to obtain a blue-purple solid compound I-2 (47.7 mg, 45%). 1 HNMR (400 MHz, DMSO- d 6 ): δ 8.52 (d, J = 16.5 Hz, 1H), 8.32 (d, J= 8.7 Hz,1H), 7.76 (d, J = 7.5 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.54 – 7.39 (m, 5H),7.07 – 6.98 (m, 2H), 6.59 (d, J = 8.8 Hz, 1H), 6.41 (d, J = 47.4 Hz, 1H),5.57 – 5.44 (m, 1H), 5.34 (s, 1H), 5.28 – 5.18 (m, 2H), 4.53 (t, J = 7.5 Hz,2H), 4.41 (dd, J = 12.4, 6.3 Hz, 1H), 4.27 (s, 2H), 4.07 (dd, J = 16.4, 6.3Hz, 2H), 3.79 (s, 2H), 3.66 – 3.36 (m, 6H), 3.15 (d, J = 17.5 Hz, 2H), 3.06 –2.95 (m, 2H), 2.17 – 2.10 (m, 7H), 2.06 – 2.00 (m, 3H), 2.00 – 1.94 (m, 3H),1.95 (s, 3H), 1.78 (s, 6H). 13 C NMR (100 MHz, DMSO- d 6 ): δ 178.85, 170.02,169.87, 169.63, 169.29, 167.85, 157.26, 149.43, 148.37, 147.16, 145.16,143.74, 142.39, 141.17, 129.60, 129.12, 128.76, 127.21, 122.74, 116.66,113.52, 107.66, 106.51, 97.38, 70.46, 70.13, 68.28, 67.21, 61.31, 59.81,53.71, 51.12, 50.61, 44.34, 41.73, 30.01, 26.51, 25.54, 24.21, 20.79, 20.46,20.38, 14.11. HRMS (ESI + ): m / zcalcd for [M-Br] + , 981.4040; found, 981.4143.
[0026] Preparation of compound I-3
[0027] (Compound I-3) Compound I-2 (106 mg, 0.10 mmol) was dissolved in methanol (10 mL), and potassium carbonate (49.5 mg, 0.50 mmol) was added. The solution was then heated to 0 mL. o Stir at C for 30 minutes. After the reaction is complete as monitored by TLC, add an appropriate amount of IR-120 plus (H + The reaction solution was observed to change from deep red to blue-purple using a type ion exchange resin. After filtration, the solvent was evaporated. The solution was then purified by wet loading onto a silica gel column (eluent: DCM / MeOH / HCOOH: 100 / 10 / 0.5, V / V), yielding a blue-purple solid compound I-3 (53.5 mg, 60.0%). 1 H NMR (400 MHz, DMSO- d 6 ) δ (ppm): δ 8.49 (d, J = 15.1 Hz, 1H), 8.29 (d, J = 8.8 Hz, 1H), 7.69 (dd, J = 29.3, 7.2 Hz, 3H), 7.54-7.36 (m,4H), 7.22 (dd, J = 14.1, 8.2 Hz, 3H), 6.96 (dd, J = 13.8, 8.3 Hz, 2H), 6.53 (d, J = 8.8 Hz, 1H), 5.15 (dd, J = 9.9, 5.1 Hz, 1H), 4.89 (s, 1H), 4.76 (dd, J =18.3, 7.4 Hz, 1H), 4.69-4.59 (m, 1H), 4.58-4.43 (m, 4H), 4.22 (s, 2H), 4.14 -4.06 (m, 1H), 3.70 (d, J = 32.3 Hz, 3H), 3.20 (s, 4H), 3.13 (d, J= 5.2 Hz, 4H), 3.02-2.92 (m, 2H), 2.09 (s, 5H), 1.74 (s, 7H). 13 C NMR (100 MHz, DMSO- d 6 )δ (ppm):168.69, 168.42, 168.33, 157.88, 149.93, 148.88, 145.67, 144.25, 142.88 , 141.65, 130.45, 129.27, 127.72, 123.24, 116.56, 113.98, 108.14, 107.03, 106. 83, 101.31, 76.00, 73.81, 70.78, 68.59, 63.32, 60.85, 57.05, 54.255, 51.65, 51. 10, 45.00, 44.53, 42.24, 38.59, 30.53, 27.00, 26.04, 24.71, 22.95, 14.45, 11.34. HRMS (ESI) m / zcalculated for C 43 H 50 BrFN6O9 [M-Br] + : 811.3661, found:811.3603.
[0028] Preparation of compound I-4
[0029] (Compound I-4) Compound I-2 (106 mg, 0.10 mmol) was dissolved in methanol (10 mL), and potassium carbonate (49.5 mg, 0.50 mmol) was added. The solution was then heated to 0 mL. o Stir at C for 30 minutes. After the reaction is complete as monitored by TLC, add an appropriate amount of IR-120 plus (H + The reaction solution was observed to change from deep red to blue-purple using a type ion exchange resin. After filtration, the solvent was evaporated. The solution was then purified by wet silica gel column loading (eluent: DCM / MeOH / HCOOH: 100 / 10 / 0.5, V / V), yielding a blue-purple solid compound I-4 (53.5 mg, 60.0%). 1 H NMR (400 MHz, CD3OD): δ 8.37 (d, J = 14.7 Hz, 1H), 8.03(d, J= 8.0 Hz, 1H), 7.62 – 7.50 (m, 3H), 7.46 (t, J = 7.4 Hz, 1H), 7.40 (d, J = 6.7 Hz, 1H), 7.34 (s, 2H), 7.15 – 7.00 (m, 2H), 6.43 (d, J = 8.7 Hz, 1H), 6.16 (dd, J = 48.7, 9.2 Hz, 1H), 4.58 (s, 2H), 4.30 (s, 2H), 3.85 (s, 1H), 3.80 – 3.61 (m, 6H), 3.54 (s, 4H), 3.43 (s, 3H), 3.04 (d, J = 21.9 Hz, 5H), 2.17 (s, 4H), 1.76 (s, 6H). 13 C NMR (100 MHz, DMSO- d 6 ): δ 178.80, 157.30,149.34, 148.34, 145.12, 143.72, 142.30, 141.09, 129.92, 129.30, 128.69,128.36, 127.14, 122.64, 116.43, 116.02, 113.41, 107.59, 106.47, 106.29,100.83, 75.48, 73.25, 70.19, 68.07, 60.34, 56.50, 53.68, 51.07, 50.53, 48.57,44.43, 41.69, 29.95, 26.46, 25.45, 24.14. HRMS (ESI + ): m / z calcd for [M-Br] + ,813.3617; found, 813.3486.
[0030] Example 2 Example 1: Preparation of benzo[a]pyrazole-indole derivatives I-3 / I-4 for detecting aging-related β-galactosidase and Aspergillus oryzae β-galactosidase ( A. oryzae Changes in UV absorption and fluorescence emission spectra before and after the reaction of β-gal and reduced bovine serum albumin (rBSA).
[0031] Accurately weigh I-3 / I-4 (8.90 mg) and dissolve it in dimethyl sulfoxide (DMSO) to prepare a 1 mmol / L stock solution. Take 20 μL of the stock solution and add it to a 2 mL centrifuge tube (final concentration 10 μM), then add 20 μL of a 180 U / mL solution. A. oryzae β-gal stock solution (final concentration 3 U / mL) was added, followed by 303 μL of rBSA stock solution (final concentration 1 mg / mL) at a concentration of 6.6 mg / mL. The system was then diluted to 2 mL with PBS buffer (0.1 M, pH = 4.5) at 37°C. o Incubate at C for 30 min, and collect fluorescence and ultraviolet absorption spectral data.
[0032] like Figure 1 As shown in Figures b and d, I-3 / I-4 in relation to... A. oryzae Significant changes in fluorescence spectra occurred after co-incubation with β-gal and rBSA solutions; the fluorescence intensity was significantly higher than that without the added solution. A. oryzae β-gal and rBSA solutions increased by 5.78 and 4.96 times, respectively. Figure 1 As shown in Figure 1, with increasing enzyme concentration (0-3 U / mL), the fluorescence at the maximum emission wavelength of the released active molecules (approximately 640 nm) gradually increased, and at a certain point... A. oryzae Within the β-gal concentration range, the fluorescence intensity at 640 nm showed a good linear relationship with the enzyme concentration.
[0033] Example 3 Example 1 shows the preparation of benzo[a]pyrazole-indole derivatives I-3 / I-4 for detecting aging-related β-galactosidase in rBSA solution. A. oryzae Selectivity and interference experiments of β-gal, as well as enzyme kinetics and pH response experiments.
[0034] I-3 / I-4 pair A. oryzae Selection and interference tests of β-gal. For example... Figure 2 As shown in a and d, a series of potential interfering substances were selected for study, including common metal ions, biothiols, other reactive oxygen species, and some anions (1. none, 2. Al). 3+ 3. NO 2- 4. CO3 2- 5. Mg 2+ 6. S2O3 2- 7. I - 8. DTT, 9. H2O2, 10. ClO -, 11. Cys, 12. Hcy, 13. GSH, 14. Gly, 15. ONOO - 16. O2 ∙- , 17.∙OH). In a PBS (0.1 M, pH = 4.5) system containing rBSA (1 mg / mL), the interfering agent has been added and does not contain A. oryzae In the β-gal stage, the fluorescence intensity of probes I-3 / I-4 is low; adding... A. oryzae The fluorescence intensity increased significantly after β-gal, indicating that probe I-3 / I-4... A. oryzae β-gal exhibits high selectivity. Similarly, even with the addition of interfering agents, [the following is observed]: A. oryzae The fluorescence intensity did not change much in the β-gal system, indicating that probes I-3 / I-4 have good anti-interference ability.
[0035] Examine I-3 / I-4 pairs A. oryzae β-gal enzyme kinetics and pH response. For example... Figure 2 As shown in Figures b, c, e, and f, in a PBS (0.1 M, pH = 4.5) system containing rBSA (1 mg / mL), 37 o C incubation, without adding A. oryzae In the case of β-gal, the autofluorescence signal of probes I-3 / I-4 is weak and remains basically unchanged. Adding... A. oryzae In the case of β-gal, fluorescence is enhanced at 640 nm and reaches its maximum after 30 min, then tends to stabilize, with the optimal response pH being 4-6.
[0036] Example 4 Example 1 describes the cytotoxicity assay of benzo[a]diazole-indole derivatives I-3 / I-4 for detecting aging-related β-galactosidase.
[0037] The MTT assay was used to investigate the cytotoxicity of different concentrations of I-3 / I-4 on A549 cells. Figure 3 As shown, after co-incubating I-3 / I-4 with A549 cells for 12 hours, the cell survival rate changed slightly. However, even at a compound concentration of 20 μM, the cell survival rate was still greater than 85% after incubation, indicating that it has good biological applicability.
[0038] Example 5 Example 1 describes a cellular confocal imaging experiment using benzo[a]diazole-indole derivatives I-3 / I-4 to detect aging-related β-galactosidase.
[0039] Cellular confocal imaging experiments were conducted to examine I-3 / I-4. First, an A549 cell senescence model was established by treatment with the inducer Mito C. X-gal staining confirmed the successful establishment of the cell senescence model. Figure 4 As shown, confocal fluorescence imaging was used to compare young and senescent A549 cells. The specific procedure was as follows: Young and senescent A549 cells were seeded into confocal culture dishes. After the cells were fully adhered, I-3 / I-4 was added and incubated for 30 minutes. Fluorescence imaging results showed that young A549 cells showed only a weak background signal in the red fluorescence channel, while senescent A549 cells showed a significant strong fluorescence signal. Notably, even after multiple PBS washes (10 times, 30 seconds each), senescent A549 cells maintained a stable fluorescence signal, indicating that I-3 / I-4 can specifically target senescence-related β-galactosidase and achieve in-situ visualization and tracing of it in senescent cells.
[0040] Example 6 Example 1 demonstrates the ability of the benzo[a]diazole-indole derivative I-4, prepared for detecting aging-related β-galactosidase, to detect senescent cells in mice.
[0041] Imaging experiments in mice were performed using an in vivo fluorescence imaging system (IVIS Spectrum / 200 imaging system) (Ex: 590 nm, Em: 640 nm). The abdominal hair of the mice was shaved before imaging. Naturally aging mice, Doxo-induced aging mice, and young mice were intraperitoneally injected with 40 mg / kg of I-4, and images were taken before injection, and at 5 minutes, 20 minutes, 1 hour, 2 hours, and 4 hours after injection. Figure 5 As shown, aging mice exhibited significant fluorescence signals compared to young mice, with the Doxo-induced aging group showing stronger fluorescence intensity than the naturally aging group. The fluorescence intensity gradually increased over time, reaching a maximum at 1 hour, and then gradually decreased. These results indicate that I-4 can detect senescent cells in mice.
[0042] It should be understood that, within the scope of this invention, the various technical features described above and in the embodiments can be combined with each other to form new or preferred technical solutions. Each feature disclosed in the specification can be replaced by any alternative feature that provides the same, equivalent, or similar purpose.
Claims
1. The benzo[a]diazole-indole derivative shown in the following structural formula, , Where R is selected from H or C1-C10 alkyl acyl groups, X is OH or F, and n = 1~10.
2. The method for synthesizing the benzo[a]diazole-indole derivative according to claim 1, characterized by comprising the following steps: (1) Compound A reacts with compound B via an organic base catalysis to yield compound C; , n = 1~10; (2) Compound C and compound D undergo an amidation reaction in the presence of a condensing agent to yield compound (I); , R is selected from H or C1-C10 alkanoyl groups, and X is OH or F.
3. The method of synthesis of benzotriazol-indole derivatives according to claim 2, characterized by the fact that: In step (1), the organic solvent used is selected from acetonitrile, methanol, ethanol, isopropanol, toluene, and benzene; the organic base used is selected from hexahydropyridine, pyridine, triethylamine, and N,N-diisopropylethylamine.
4. The method of synthesis of benzotriazol-indole derivatives according to claim 2, characterized by the fact that: In step (2), the organic solvent used is selected from acetonitrile, dichloromethane, 1,4-dioxane, tetrahydrofuran, and N,N-dimethylformamide; the organic base used is selected from hexahydropyridine, pyridine, triethylamine, and N,N-diisopropylethylamine; and the condensing reagent used is selected from 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and benzotriazole-1-yl-oxytripyrrolidinephosphide hexafluorophosphate.
5. The method for synthesizing benzo[a]diazole-indole derivatives according to claim 2, characterized in that: In step (2), compound I-OH, where X is OH, reacts with a fluorinating reagent to obtain compound IF. The fluorinating reagent is selected from diethylaminosulfur trifluoride, N-fluorobisbenzenesulfonamide, sulfomorpholine trifluoride, or bis-(2-methoxyethyl)aminesulfur trifluoride. 。 6. The method for synthesizing benzo[a]diazole-indole derivatives according to claim 5, characterized in that: The organic solvents used are selected from acetonitrile, dichloromethane, 1,4-dioxane, tetrahydrofuran, and N,N-dimethylformamide.
7. The method for synthesizing benzo[a]diazole-indole derivatives according to claim 2, characterized in that: In step (2), compound IR, with R being a C1-C10 alkanoyl group, undergoes transesterification to yield compound IH; 。 8. The method for synthesizing benzo[a]diazole-indole derivatives according to claim 7, characterized in that: The organic solvent used in the reaction is selected from acetonitrile, dichloromethane, 1,4-dioxane, tetrahydrofuran, and N,N-dimethylformamide, and the inorganic base is selected from potassium carbonate, sodium carbonate, and cesium carbonate.
9. The benzo[a]diazole-indole derivative of claim 1 has one or more of the following applications: (1) A composition or preparation for the detection of β-galactosidase; (2) Compositions or preparations for the preparation of samples for detecting β-galactosidase activity at the molecular, cellular and in vivo animal levels; (3) Compositions or preparations for selectively recognizing and anchoring cells with high expression of β-galactosidase.
10. Pharmaceutical compositions, cosmetic compositions, food compositions, or health product compositions comprising the benzo[a]diazole-indole derivative of claim 1.
